Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL77417 | 0.98 | SLC6A4 (0.36) | SLC6A4SLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL17309305 | 0.94 | SLC6A4 (0.33) | SLC6A4SLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL27389747 | 0.94 | SLC6A4 (0.33) | SLC6A4SLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL15362827 | 0.94 | SLC6A4 (0.33) | SLC6A4SLC6A2SLC6A3HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL17293798 | 0.92 | SLC6A4 (0.33) | SLC6A4SLC6A2SLC6A3HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL15352369 | 0.92 | SLC6A4 (0.33) | SLC6A4SLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL6043580 | 0.87 | SLC6A4 (0.35) | SLC6A4SLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL18912341 | 0.87 | CHRM1 (0.39) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL13853932 | 0.87 | CHRM1 (0.39) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL21638302 | 0.87 | CHRM1 (0.39) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260109677-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12522571-B2 | Compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250257057-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.I. (IT) | 2025-08-14 | — | — | US | disclosed |
| US-12258337-B2 | Bicyclic CX3CR1 receptor agonists | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-25 | — | — | US | disclosed |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240279187-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-114929681-B | Bicyclic CX3CR1 receptor agonists | 德州大学系统董事会 | 2024-05-14 | — | — | CN | disclosed |
| US-20240150332-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.L. (IT) | 2024-05-09 | — | — | US | disclosed |
| US-11958839-B2 | Bicyclic CX3CR1 receptor agonists | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-16 | — | — | US | disclosed |
| EP-1945220-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007046548-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| CN-1826340-A | Pyrrolopyridine-2-carboxylic acid amides as glycogen phosphorylase inhibitors | PROSIDION LTD (GB) | 2006-08-30 | — | — | CN | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| US-4237138-A | REGULATORS OF CARDIOVASCULAR SYSTEM | PFIZER INC. (US) | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | SLC6A4 4166/4885SLC6A2 4036/4885SLC6A3 2991/4885 |
| US-12258337-B2 | Bicyclic CX3CR1 receptor agonists | CX3CR1, CCR2, CCR5 | SLC6A4 2786/4885SLC6A2 3547/4885SLC6A3 2555/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | SLC6A4 3787/4885SLC6A2 3760/4885SLC6A3 3711/4885 |
| US-20250257057-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | CX3CR1, CCR2, CCR5 | SLC6A4 2786/4885SLC6A2 3547/4885SLC6A3 2555/4885 |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PYGL, PYGM, PYGB | SLC6A4 4170/4885SLC6A2 3258/4885SLC6A3 4298/4885 |
| US-20240279187-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | SLC6A4 204/4885SLC6A2 61/4885SLC6A3 130/4885 |
| US-11958839-B2 | Bicyclic CX3CR1 receptor agonists | CX3CR1, CCR2, CCR5 | SLC6A4 2786/4885SLC6A2 3547/4885SLC6A3 2555/4885 |
| US-20260109677-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | NR3C2, AGTR1, CHRM1 | SLC6A4 1107/4885SLC6A2 311/4885SLC6A3 436/4885 |
| US-20240150332-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | CX3CR1, CCR2, CCR5 | SLC6A4 2786/4885SLC6A2 3547/4885SLC6A3 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.